C&CURE & ADVANCEMENTS
Cure & Advancements/November 18, 2026/2 min read

Gene-Edited Insulin Cells Survive Without Rejection Drugs in Early Human Test

Researchers successfully hid donor insulin-producing cells from the immune system using gene editing, and the cells survived and functioned in one patient for over a year. This early result offers a new direction for cell transplant therapy, though much larger studies are needed.

Research summaryVideo report, corroborated with 1 indexed study

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

  • Scientists used gene editing to mask donor insulin cells so the immune system couldn't recognize them as foreign
  • In one adult patient, these edited cells remained alive and producing insulin for 14 months without anti-rejection medications
  • The patient still requires insulin therapy, showing the transplant is supplementary, not a replacement for existing diabetes management
  • This was a small, controlled early-stage test—findings cannot yet be generalized to larger groups or other age groups
  • A larger trial of a stem-cell version of this approach is planned for the future

What Researchers Tried

Scientists at Sana Biotechnology and Uppsala University Hospital took insulin-producing cells from a donor and used gene editing to remove markers that alert the immune system to foreign tissue. The goal was to make the cells 'invisible' so they could survive without the immunosuppressive drugs typically needed after transplants.

The edited cells were then transplanted into one adult living with Type 1 diabetes in a carefully controlled, early-stage test using a deliberately small dose.

What Happened

Fourteen months after the transplant, the gene-edited cells were still alive and producing some insulin. Critically, the patient did not require anti-rejection drugs during this time, which is a major difference from standard cell transplant approaches.

However, the patient continued to use insulin therapy throughout the study. This shows that while the transplanted cells contributed to insulin production, they did not eliminate the need for insulin management.

Important Context

This was a single-person trial with a deliberately low transplant dose—a proof-of-concept rather than a full-scale test. Results from one patient cannot be applied to larger populations or other groups.

The approach has not yet been tested in children. A larger clinical trial using a stem-cell derived version (called SC451) is now planned to explore whether these results hold up in more patients.

Why This Matters

If gene-edited cell transplants can survive without lifelong immunosuppressive drugs, they could become a valuable therapeutic option for people with Type 1 diabetes. Avoiding anti-rejection medications would reduce serious side effects and simplify long-term management.

This work also reflects a broader scientific effort to understand how immune cells and insulin-producing cells communicate—research that may reveal new ways to both protect transplanted cells and support the body's own insulin production.

Evidence label

Origin: T1D Cure Watch (Video report). Evidence: Video report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.